Expert Insights: In Conversation with Prof. Adi Barzel

At UNLOKall, we bring together leading voices shaping the future of oncology, gene therapy, and cellular engineering. Through our expert interviews, we explore real-world perspectives on scientific innovation, translational research, and emerging therapies, helping clinicians and researchers bridge the gap between discovery and patient care.

Meet the Expert

Prof. Adi Barzel

Prof. Adi Barzel recently participated in the UNLOKall webinar Approved and Emerging Lymphocyte Engineering Technologies in collaboration with ICLE. Watch the recording here.

Scientist, inventor, and entrepreneur specializing in gene therapy, immunotherapy, and genome editing. He has co-founded several biotech companies, including LogicBio Therapeutics and Tabby Therapeutics, and has been instrumental in developing transformative treatments from bench to bedside. Prof. Barzel serves as president of the Israeli Society of Gene and Cell Therapy and chairs the International Conference on Lymphocyte Engineering.

From your perspective, what makes initiatives like the ICLE webinar series particularly valuable for today’s oncology and research community?

The Translation Bridge: The distance between a laboratory breakthrough and an approved, clinic-ready therapeutic is immense. Initiatives like the ICLE webinar series are invaluable because they bridge this gap in real time. By focusing on both “Approved and Emerging Therapies” as well as granular bottleneck challenges—such as solid tumor penetration—these webinars provide a dynamic forum. They allow researchers to see where the clinical needs are, and they give clinicians a preview of the next-generation engineering platforms (such as in vivo reprogramming or advanced vector design) that will define tomorrow’s standard of care.

In fields characterized by rapid scientific and technological progress, what are the key challenges professionals face when trying to stay up to date?

Information Velocity vs. Translational Focus: The sheer volume and velocity of data generated in lymphocyte engineering—from novel CRISPR variants to evolving synthetic biology architectures—is overwhelming. For a busy clinician or researcher, the primary challenge isn’t access to information, but filtering the noise. It is incredibly difficult to discern which emerging platform holds genuine clinical promise versus what is merely an incremental laboratory finding. Furthermore, navigating the rapidly shifting regulatory, manufacturing, and safety landscapes alongside basic science creates a massive cognitive load for professionals trying to advance therapies safely.

How do expert‑driven educational platforms contribute to better understanding, collaboration, and confidence among clinicians and researchers?

Curated Insight and Clinical Confidence: Expert-driven platforms do what a simple literature search cannot: they provide context, critical curation, and nuance. When pioneers in cellular therapy share their insights, they don’t just report successful outcomes; they openly address the roadblocks—manufacturing failures, unexpected toxicities, or delivery hurdles. This transparency builds immense confidence in clinicians who must make high-stakes decisions, and it fosters a collaborative ecosystem where researchers can align their engineering priorities with actual clinical reality.

Why is it important to bring together diverse perspectives through learning initiatives such as webinars, and how does this benefit the broader community?

Breaking the Silos: Lymphocyte engineering is fundamentally multidisciplinary. A successful therapeutic requires the harmony of molecular biology, viral and non-viral vector engineering, immunology, oncology, and industrial manufacturing. If we remain in our academic or clinical silos, progress stalls. Webinars democratize access to this collective intelligence, allowing a vector biologist to understand the physical barriers of a solid tumor, or a clinical oncologist to appreciate the nuances of T-cell fitness. This cross-pollination accelerates the entire field, ensuring that innovations are scalable and clinically viable from inception.

What would you encourage participants to focus on as they continue engaging with the ICLE webinar series and similar educational programs?

Focus on the Bottlenecks: I would encourage participants to move beyond the excitement of initial efficacy data and focus intensely on the remaining biological and logistical bottlenecks. Pay close attention to discussions surrounding delivery mechanisms, long-term persistence, overcoming the immunosuppressive tumor microenvironment, and scalability. The future of the field relies on making these highly sophisticated therapies safer, more precise, and ultimately, accessible to a broader patient population. Use these sessions not just to consume information, but to identify the specific challenges your own work can help solve.

Learn from Prof. Adi Barzel